Supplemental data (unaudited)

The following information is presented as supplemental data as required by the indentures governing the Company’s Senior Notes.

Condensed Consolidating Statements of Income



	Consolidated Total			Physician Groups		Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
For the year ended December 31, 2017
Dialysis and related lab patient service revenues	$	10,093,670		$	—	$	—	$	10,093,670
Less: Provision for uncollectible accounts	(485,398		)	—		—		(485,398		)
Net dialysis and related lab patient service revenues	9,608,272			—		—		9,608,272
Other revenues	1,268,362			—		—		1,268,362
Total net revenues	10,876,634			—		—		10,876,634
Operating expenses and charges	9,063,879			—		—		9,063,879
Operating income	1,812,755			—		—		1,812,755
Debt expense	(430,634		)	—		—		(430,634		)
Other income, net	17,665			—		—		17,665
Income tax expense	323,859			—		—		323,859
Net income from continuing operations	1,075,927			—		—		1,075,927
Net (loss) income from discontinued operations, net of tax	(245,372		)	13,611		19		(259,002		)
Net income	830,555			13,611		19		816,925
Less: Net income attributable to noncontrolling interests	(166,937		)	7,183		—		(174,120		)
Net income attributable to DaVita Inc.	$	663,618		$	20,794	$	19	$	642,805

Condensed Consolidating Statements of Comprehensive Income



	Consolidated Total			Physician Groups		Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
For the year ended December 31, 2017
Net income	$	830,555		$	13,611	$	19	$	816,925
Other comprehensive income	102,876			—		—		102,876
Total comprehensive income	933,431			13,611		19		919,801
Less: Comprehensive income attributable to noncontrolling interest	(166,935		)	7,183		—		(174,118		)
Comprehensive income attributable to DaVita Inc.	$	766,496		$	20,794	$	19	$	745,683


(1)	After the elimination of the unrestricted subsidiaries and the physician groups

Condensed Consolidating Balance Sheets



	Consolidated Total		Physician Groups		Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
As of December 31, 2017
Cash and cash equivalents	$	508,234	$	—	$	—	$	508,234
Accounts receivable, net	1,714,750		—		—		1,714,750
Other current assets	759,732		3,033		—		756,699
Other current assets held for sale	5,761,642		423,205		2,733		5,335,704
Total current assets	8,744,358		426,238		2,733		8,315,387
Property and equipment, net	3,149,213		—		—		3,149,213
Amortizable intangibles, net	113,827		—		—		113,827
Other long-term assets	330,516		—		—		330,516
Goodwill	6,610,279		—		—		6,610,279
Total assets	$	18,948,193	$	426,238	$	2,733	$	18,519,222
Current liabilities	$	1,856,107	$	—	$	—	$	1,856,107
Current liabilities held for sale	1,185,070		308,884		—		876,186
Total current liabilities	3,041,177		308,884		—		2,732,293
Payables to parent	—		—		2,733		(2,733		)
Long-term debt and other long-term liabilities	10,009,590		—		—		10,009,590
Noncontrolling interests subject to put provisions	1,011,360		—		—		1,011,360
Total DaVita Inc. shareholders' equity	4,690,029		117,354		—		4,572,675
Noncontrolling interests not subject to put provisions	196,037		—		—		196,037
Shareholders' equity	4,886,066		117,354		—		4,768,712
Total liabilities and shareholders' equity	$	18,948,193	$	426,238	$	2,733	$	18,519,222

Condensed Consolidating Statements of Cash Flow



	Consolidated Total			Physician Groups			Unrestricted Subsidiaries			Company and Restricted Subsidiaries⁽¹⁾
For the year ended December 31, 2017
Cash flows from operating activities:
Net income	$	830,555		$	13,611		$	19		$	816,925
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	1,076,894			27,312			(19		)	1,049,601
Net cash provided by operating activities	1,907,449			40,923			—			1,866,526
Cash flows from investing activities:
Additions of property and equipment	(905,250		)	(5,406		)	—			(899,844		)
Acquisitions and divestitures, net	(803,879		)	—			—			(803,879		)
Proceeds from asset sales	92,336			—			—			92,336
Investments and other items, net	250,062			(3,800		)	—			253,862
Net cash used in investing activities	(1,366,731		)	(9,206		)	—			(1,357,525		)
Cash flows from financing activities:
Long-term debt and related financing costs, net	154,848			—			—			154,848
Intercompany	—			(36,220		)	—			36,220
Other items	(921,105		)	—			—			(921,105		)
Net cash used in financing activities	(766,257		)	(36,220		)	—			(730,037		)
Effect of exchange rate changes on cash	254			—			—			254
Net decrease in cash and cash equivalents	(225,285		)	(4,503		)	—			(220,782		)
Less: Net decrease in cash and cash equivalents from discontinued operations	(58,743		)	(4,503		)	—			(54,240		)
Net decrease in cash and cash equivalents from continuing operations	(166,542		)	—			—			(166,542		)
Cash and cash equivalents of continuing operations at beginning of the year	674,776			—			—			674,776
Cash and cash equivalents of continuing operations at end of the year	$	508,234		$	—		$	—		$	508,234


(1)	After the elimination of the unrestricted subsidiaries and the physician groups